Barr files paragraph IV on Zyprexa

-->Barr Pharmaceuticals, Inc. announced on Dec. 2, 2004 that its subsidiary, Barr Laboratories, Inc., has initiated the challenge of the patent listed by Eli Lilly and Company in connection with Eli Lilly's ZYPREXA® Zydis® (Olanzapine) Orally Disintegrating Tablets, 5mg, 10mg, 15mg and 20mg.<--

A ruling in a different Zyprexa case is expected soon.